

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients

Yufeng Song¹, Regan Myers¹, Lila Murphy^{1,2}, Bailey Brooks^{1,2}, Jeffrey M. Wilson³,
Alexandra Kadl^{4,5}, Judith Woodfolk⁴, Steven L. Zeichner^{1,6*}

¹Department of Pediatrics, University of Virginia

²College of Arts and Sciences, University of Virginia

³Division of Allergy and Clinical Immunology, Department of Medicine, University of Virginia

⁴Department of Medicine, University of Virginia

⁵Department of Pharmacology, University of Virginia

⁶Department of Microbiology, Immunology, and Cancer Biology, University of Virginia

*Correspondence: zeichner@virginia.edu

22 **Abstract**

23 Many mechanisms responsible for COVID-19 pathogenesis are well-established, but
24 COVID-19 includes features with unclear pathogenesis, such as autonomic
25 dysregulation, coagulopathies, and high levels of inflammation. The receptor for SARS-
26 CoV-2 spike protein's receptor binding domain (RBD) is angiotensin converting enzyme
27 2 (ACE2). We hypothesized that some COVID-19 patients may develop antibodies that
28 have negative molecular image of RBD sufficiently similar to ACE2 to yield ACE2-like
29 catalytic activity – ACE2-like abzymes. To explore this hypothesis, we studied patients
30 hospitalized with COVID-19 who had plasma samples available obtained about 7 days
31 after admission. ACE2 is a metalloprotease that requires Zn^{2+} for activity. However, we
32 found that the plasma from some patients studied could cleave a synthetic ACE2
33 peptide substrate, even though the plasma samples were collected using disodium
34 ethylenediaminetetraacetate (EDTA) anticoagulant. When we spiked plasma with
35 synthetic ACE2, no ACE2 substrate cleavage activity was observed unless Zn^{2+} was
36 added or the plasma was diluted to decrease EDTA concentration. After processing
37 samples by 100 kDa size exclusion columns and protein A/G adsorption, which
38 depleted immunoglobulin by >99.99%, the plasma samples did not cleave the ACE2
39 substrate peptide. The data suggest that some patients with COVID-19 develop
40 antibodies with abzyme-like activity capable of cleaving synthetic ACE2 substrate. Since
41 abzymes can exhibit promiscuous substrate specificities compared to the enzyme
42 whose active site image they resemble, and since proteolytic cascades regulate many
43 physiologic processes, anti-RBD abzymes may contribute to some otherwise obscure
44 COVID-19 pathogenesis.

45

46

47 **Introduction**

48 The primary pathology in COVID-19 involves pulmonary disease¹⁻³. Other end organ
49 involvement, likely directly attributable to infection with the virus, can include
50 gastrointestinal disease, such as diarrhea, and loss of smell and taste²⁻⁴. While the
51 basic pathophysiology of COVID-19 is well-established, COVID-19 has many baffling
52 features, including disorders involving high inflammation, disorders of the clotting
53 cascade, and problems with blood pressure homeostasis^{2, 5, 6}. Some sequelae do not
54 develop until a week or more after infection, suggesting that their pathogenesis may
55 result from secondary processes.

56
57 Reports suggest that some of the inflammatory processes associated with COVID-19
58 may relate to antibodies against the SARS-CoV-2 spike protein, S. For example, small
59 numbers of children who have received COVID-19 vaccines and have had no evidence
60 of infection with SARS-CoV-2, as well as a small number of infants born to mothers with
61 COVID-19⁷ have been described as having multi-system inflammatory syndrome of
62 children (MIS-C)⁸.

63
64 In addition to acute COVID-19, some patients experience Post-Acute Sequelae of
65 SARS CoV-2 infection (PASC, sometimes called “long COVID”), a heterogeneous group
66 of symptoms that continue after acute infection has resolved and can include evidence
67 of a hyperinflammatory state⁹, persistent coagulopathies, and neurophysiologic
68 dysregulation, for example aberrant blood pressure regulation. While some clinical
69 features observable at the beginning of the COVID-19 clinical course, such as SARS-
70 CoV-2 viremia, autoantibodies, inflammatory markers, and activation of Epstein-Barr

71 Virus, may be associated with an increased risk of long COVID¹⁰, the detailed
72 pathogenic processes responsible for PASC remain unclear.
73
74 Membrane-bound angiotensin converting enzyme 2 (ACE2) is the main cellular receptor
75 for SARS-CoV-2. Binding of the SARS-CoV-2 spike protein receptor binding domain
76 (RBD) to ACE2 initiates the pathway that leads to infection of a new host cell. ACE2, a
77 Zn²⁺ metalloenzyme, cleaves angiotensin II into angiotensin 1-7, which has vasodilatory
78 activity. Angiotensin converting enzyme (ACE) cleaves angiotensin I to yield angiotensin
79 II, which has vasoconstrictive and hypertensive effects. ACE2 therefore helps to
80 counteract the hypertensive effects of angiotensin II, and so has blood pressure
81 counterregulatory activity compared to ACE. There have been isolated reports and
82 small case series describing persistent hypotension in patients with COVID-19 and
83 patients with PASC without a clearly identified cause¹¹⁻¹³.
84
85 The kallikrein-kinin system is a proteolytic cascade that helps regulate inflammation
86 (reviewed in ¹⁴). There is cross-talk between the coagulation, kallikrein-kinin,
87 complement and renin-angiotensin systems¹⁵. Some patients with severe COVID-19
88 respiratory disease have been found to have altered regulation of the kallikrein-kinin
89 system in bronchoalveolar lavage fluid¹⁶. Abnormalities in the kallikrein-kinin system
90 have been proposed as contributing to the pathogenesis of severe COVID-19¹⁷.
91
92 Catalytic antibodies, “abzymes”^{18, 19}, are antibodies that have catalytic activity. When
93 abzymes were first described, they generated considerable excitement. Investigators
94 hypothesized that it would be possible to produce clinically and biotechnologically useful
95 abzymes.

96

97 However, with additional studies, it became clearer that abzyme activity was
98 significantly lower than the activity of more conventional enzymes (k_{cat}/K_m values $\sim 10^2$
99 $- 10^4 \text{ s}^{-1} \cdot \text{M}^{-1}$ vs. k_{cat}/K_m values of $\sim 10^5 \text{ s}^{-1} \cdot \text{M}^{-1}$)²¹. Hence, interest in the
100 biotechnological applications of abzymes waned, but an appreciation of the potential
101 role of abzymes in the pathogenesis of disease, including autoimmune disease,
102 continued. High concentrations of abzymes in the circulation may compensate for the
103 abzymes' lower activity to yield clinically significant effects.

104

105 Patients with autoimmune diseases can make abzymes catalyzing, for example,
106 cleavage of vasoactive intestinal peptide (VIP)²², DNA²³, immunoglobulin components²⁴,
107 components of the clotting cascade²⁵⁻²⁷, and myelin basic protein (MBP) in patients with
108 multiple sclerosis²⁸. Abzymes that cleave the HIV envelope protein have been observed
109 to occur in patients with HIV, so there is precedence for the induction of a catalytic
110 antibody by a virus²⁹.

111

112 Investigators have deliberately made anti-idiotypic abzymes with catalytic activity like
113 the activity of a particular enzyme of interest^{30, 31}. Investigators identify an antibody
114 against an enzyme, and then produce an antibody against the anti-enzyme antibody.
115 For some of the anti-idiotypic antibodies, there is enough resemblance to the active site
116 of the enzyme that the anti-idiotypic antibody has catalytic activity resembling the
117 enzyme^{32, 33}. In some instances, the substrate specificity of the abzyme differs
118 substantially from that of the original enzyme^{31, 32, 34}, with the abzyme showing more
119 substrate promiscuity than the original enzyme.

120

121 The receptor binding domain of the SARS-CoV-2 spike protein uses the ACE2 enzyme
122 on the surface of the target future host cell as its receptor. The RBD is not an antibody,
123 but it does bind ACE2. Taking as an example of abzyme production the anti-idiotypic
124 antibody to an antibody against an enzyme, it is plausible to hypothesize that in some
125 cases, an antibody against the RBD might resemble the ACE2 active site and so have
126 catalytic activity. If an antibody directed against the RBD has some resemblance to
127 ACE2, it is also plausible that anti-RBD antibodies, for some small fraction of patients,
128 might have catalytic activity reminiscent of ACE2. We hypothesized that some COVID-
129 19 patients may develop anti-RBD antibodies, with promiscuous catalytic activity that, in
130 some cases, cleaves substrates in patients to yield clinically significant effects. FIG 1
131 outlines this hypothesis schematically. We therefore undertook a study to explore
132 whether some COVID-19 patients might have antibodies that can cleave an ACE2
133 substrate.

134

135 We studied plasma samples from a group of 67 patients, with samples obtained
136 relatively early in their disease course, on about the 7th day of hospitalization. As a
137 negative control we purchased pooled human plasma that was collected in late 2018,
138 about a year before the first cases of COVID-19 were described. We tested plasma
139 using an established fluorometric assay for ACE2 activity, which detects cleavage of an
140 ACE2 peptide substrate. We found that some of the patients had ACE2 substrate
141 peptide cleavage activity when the assay was run directly on disodium
142 ethylenediaminetetraacetate (EDTA)-anticoagulated plasma samples, even though
143 ACE2 is a metalloprotease that requires Zn^{2+} for activity. Recombinant ACE2 added to
144 plasma did not show ACE2 substrate-cleaving activity unless $ZnCl_2$ was added to
145 samples at concentrations greater than the EDTA. Processing the samples through a

146 100 KDa size exclusion column followed by absorption with protein A/G beads, which
147 depleted IgG by >99.99%, eliminated the ability of the samples to cleave the ACE2
148 peptide substrate, supporting the hypothesis that a fraction of COVID-19 patients may
149 develop antibodies that have ACE2 substrate cleavage activity.

150

151

152 **Methods**

153 **Clinical Cohort**

154 The clinical cohort was recently described in more detail in another publication³⁵. The
155 hypothesis motivating that work held that COVID-19 would lead to large scale
156 reactivation of lymphotropic herpesviruses EBV and HHV-6, but the data obtained in
157 the study did not support that hypothesis. In brief, the University of Virginia (UVA)
158 enrolled a prospective cohort of moderate to severe COVID-19 adult patients admitted
159 to the hospital with a diagnosis confirmed by a nucleic acid amplification test. Patients
160 consented were entered into the study. Clinical data were entered into study databases.
161 Plasma was collected into clinical standard lavender top (EDTA anticoagulant) tubes.
162 Samples were processed in the UVA Biorepository and Tissue Facility and stored at -80
163 C. Study participants (n=67) were adults ages 18 years and above. We used samples
164 obtained on or about day 7 of hospitalization for this study, prior to anti-inflammatory
165 drug administration. The predominant viral strain for our sample was the alpha strain
166 with 98.51% of our sample (66 patients) being collected before July of 2021. The sample
167 collection protocol was approved by the UVA IRB (HSR #200110), and approval was
168 obtained to work on the specimens (HSR #HSR200362), and it follows the
169 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
170 guidelines. EDTA-anticoagulated healthy normal donor plasma was purchased from
171 Valley Biomedical (<http://www.valleybiomedical.com/>), (Pooled Human Plasma, Cat. No.
172 HP1051PK2, Lot No. 21M2548). This lot of plasma was collected on December 12,
173 2018 and December 13, 2018 (communication with Valley Biomedical technical
174 support), about a year before the start of the COVID-19 pandemic, so it is extremely
175 unlikely that the plasma was derived from any blood from patients infected with SARS-

176 CoV-2. Plasma was aliquoted and stored at -20°C according to manufacturer's

177 instructions.

178

179 **Angiotensin II Converting Enzyme (ACE2)-like Abzyme Activity Detection**

180 Abzyme catalytic activities in plasma samples were measured using an Angiotensin II

181 Converting Enzyme (ACE2) Activity Assay Kit, Fluorometric (Abcam, Cat. #ab273297)

182 according to the manufacturer's protocol. This assay employs a synthetic ACE2 peptide

183 substrate labeled with a fluor and a quencher. The manufacturer's product information

184 claims a lower limit of detection for an unmodified assay of 400 μ U. The manufacturer

185 does not release detailed information concerning the peptide substrate, holding that

186 information as a trade secret. The kit includes recombinant human ACE2 (ACE2) for

187 use as a positive control. 50 μ l plasma was added to wells in a 96-well black flat bottom

188 assay plate (Corning, Cat. #3603) and incubated at room temperature (RT), in the dark

189 for 15 min. Then, 50 μ l of substrate pre-diluted according to manufacturer's protocol was

190 added into the wells of the plate, mixing the substrate with the plasma sample. The

191 plate was immediately placed into a SpectraMax® M5 multi-model microplate reader

192 (Molecular Devices) and the Relative Fluorescent Unit (RFU, Ex/Em = 320/420 nm)

193 values were measured in kinetic mode every 20 min for a total of 16 hours at 37°C.

194 ACE2 inhibitor provided in the assay kit was also used for additional controls.

195

196 **Determination of ACE2 Substrate Peptide Cleavage Activity in Plasma Samples**

197 **With and Without Added ZnCl₂ or Plasma Dilution**

198 To evaluate whether native ACE2 shed into blood^{36, 37} could contribute to the catalytic

199 activity observed in the patient plasma samples, we investigated whether EDTA present

200 in the plasma samples inhibited activity of recombinant ACE2 spiked into the samples.
201 EDTA can inhibit the catalytic activity of ACE2, a Zn²⁺ metalloprotease^{38, 39}.
202
203 We conducted serial 10-fold dilutions of the normal donor plasma in ACE2 assay buffer
204 from the assay kit and then added and then added 2 μL recombinant positive control
205 ACE2, provided as a positive control in the ACE2 assay kit (Abcam, Cat. #ab273297) to
206 each well to the samples to the samples according to the manufacturer's protocol,
207 conducting the ACE2 assays on the serially diluted samples with the added
208 recombinant ACE2. We also added ZnCl₂ to some samples to achieve final
209 concentrations ranging from 0 to 2 mM. Samples containing plasma, recombinant ACE2
210 and ZnCl₂ mixture with pre-diluted ACE2 inhibitor served as negative comparisons.
211 Then, 50 μL of substrate (pre-diluted according to manufacturer's protocol) was added
212 into the wells. Relative Fluorescent Units were measured, and data was analyzed as
213 described below.

214

215 **Human Immunoglobulin Depletion and Detection**

216 To deplete immunoglobulins from the samples, patient plasma samples or pooled
217 healthy donor plasma were centrifuged at 12,000 g at 4 °C for 15 min and supernatants
218 were passed through 0.45 μm syringe filter (FisherScientific, Cat. #97204) to remove
219 contaminating particulate matter. We then placed 500 μL of the filtered samples into
220 ultrafiltration columns with 100kDa cut-off ultrafiltration membrane (Pierce™ Cat. #
221 88503) and centrifuged the columns at 12,000 × g at 4 °C until > 400 μL of filtrate was
222 produced. To further deplete antibodies in the plasma samples, we then incubated the
223 flow-through fractions with 30 μL pre-washed Protein A/G Magnetic Beads (Life
224 Technologies, Cat. # 88803, 10 mg/mL) at room temperature (RT) for 1 hour, followed

225 by magnetic removal of the beads, and repeated the same incubation procedure with
226 another freshly prepared 30 μ L magnetic beads. The resulting processed plasma
227 samples were stored at 4°C for short times (less than 12 hours) or -20 °C for longer
228 times. Human IgG was measured using a Human IgG ELISA Kit (Abcam, Cat.
229 #ab100547) according to the manufacturer's protocol. We added 50 μ L processed
230 samples, as well as standards to multi-microwell strips and incubated them at room
231 temperature for 2.5 hours. Strips were washed with wash buffer and 50 μ L diluted
232 biotin-labeled IgG detection antibody were then added to each well with subsequent
233 HRP-streptavidin incubation after another wash step. Each incubation was performed at
234 room temperature for at least 1 hour. After washing, 100 μ L of TMB One-Step Substrate
235 was added to each well and was incubated for 5 to 15 min at room temperature in the
236 dark with gentle shanking. The reaction was stopped by adding 50 μ L Stop Solution to
237 each well. OD values were read at 450 nm using an accuSkan FC micro-well plate
238 reader (ThermoFisher). IgG concentrations were calculated based on standard curves
239 generated with the same batch of assay strips. Human IgM was measured using a
240 Human IgM ELISA Kit (Invitrogen, Cat. #BMS2098) according to the manufacturer's
241 protocol. Briefly, after washing the strips twice, we added 100 μ L processed samples,
242 as well as standards together with 50 μ L HRP-conjugated antibody to multi-microwell
243 strips and incubated them at room temperature for at least 1 hour. Strips were washed
244 with wash buffer. After washing, 100 μ L of TMB One-Step Substrate was added to each
245 well and was incubated for 5 to 15 min at room temperature in the dark with gentle
246 shanking. The reaction was stopped by adding 100 μ L Stop Solution to each well. OD
247 values were read at 450 nm using an accuSkan FC micro-well plate reader
248 (ThermoFisher). IgM concentrations were calculated based on standard curves
249 generated with the same batch of assay strips.

250

251 **RBD Binding Assays**

252 We measured IgG binding to the S-RBD in serum with a quantitative ImmunoCAP™-
253 based system, employing a Phadia 250 (Thermo-Fisher/Phadia), as described⁴⁰. In
254 brief, we biotinylated S-RBD (RayBiotech, Peachtree Corners, GA) and conjugated it to
255 streptavidin-coated ImmunoCAP™s (Thermo-Fisher/Phadia). We subtracted
256 background signal by subtracting the signal due to unconjugated streptavidin
257 ImmunoCAP™, which was run in parallel with each sample.

258

259 **Data Analysis**

260 Since the RFU values for the assays conducted on the samples reached 80% of
261 maximum at about 240 min, RFU values observed over 240 min generated by an ACE2
262 kit were used to evaluate ACE2 substrate cleavage activity in the plasma samples. For
263 each sample, a value corrected for baseline fluorescence in the sample was obtained
264 by the subtracting the baseline RFU value from the value at each subsequent time and
265 the sum of the baseline-corrected RFU values over 240 min was calculated using Excel.
266 Subsequent statistical analysis and data visualization was done using R (version 4.2.1)
267 with the Rstudio environment and packages ggplot2, tidyverse, readr, drc, ggpubr,
268 ggh4x, gridExtra, and scales. Samples with the top 20% and a control bottom 10% RFU
269 values over 240 min were identified for antibody depletion and further assays.

270

271

272 Results

273 To develop assays with enhanced sensitivity for ACE2 substrate cleavage activity, we
274 used a commercially available kit, in which a synthetic peptide ACE2 substrate labeled
275 with a fluor and a quencher is exposed to sample. ACE2 substrate cleavage activity
276 frees the fluor from quenching, followed by fluorometric evaluation over time. We first
277 established the kit's performance characteristics on commercially purchased EDTA-
278 anticoagulated normal human plasma. ACE2 is a Zn²⁺-requiring metalloenzyme. Since
279 EDTA was used as the anticoagulant, to make Zn²⁺ unavailable to the Zn²⁺-requiring
280 metalloenzymes of the enzymes involved in the coagulation cascade, we first
281 established whether exogenously added ACE2 could be detected when added to
282 plasma samples under our assay conditions. We found that exogenously added
283 recombinant ACE2 could not be detected, either using commercially obtained pooled
284 plasma or in plasma samples pooled from our patients and obtained from our sample
285 bank, unless Zn²⁺ was added or unless the plasma was diluted (FIG 2). Since no native
286 ACE2 activity should be detectable in the EDTA-anticoagulated plasma, any ACE2
287 substrate cleavage activity observed in the EDTA-anticoagulated plasma should be due
288 to something other than ACE or another Zn²⁺ metalloprotease.

289
290 We performed the ACE2 assay on EDTA-anticoagulated (obtained using clinical
291 standard lavender top tubes) research participant plasma samples obtained at about the
292 7th day of hospitalization for a cohort of 67 COVID-19 patients with moderate to severe
293 disease. Using these samples, without dilution and without added Zn²⁺, we found that
294 we could detect cleavage of the ACE2 peptide substrate in some of the patients,
295 suggesting that the ACE2 peptide substrate cleavage activity was produced by an agent

296 with co-factor characteristics different from canonical ACE2 (FIG 3). FIG 4 shows a
297 scatter plot of the RFU values for the 67 patients studied.

298
299 To determine whether the ACE2 substrate cleavage activity was associated with the
300 presence of immunoglobulin in the samples, we developed an immunoglobulin depletion
301 protocol that includes an initial 0.45 um filtration step to remove large aggregates,
302 followed by a 100 KDa size exclusion column chromatography step, and a subsequent
303 staphylococcal A/G bead absorption step. To test whether patients with high RFU had
304 ACE2 substrate cleavage activity associated with immunoglobulin, we selected samples
305 from patients who had RFU values in the top 20% RFU values and which still had
306 sufficient plasma samples remaining for the immunoglobulin depletion procedure and
307 subsequent ACE2 assays. This selection yielded samples from 11 patients, 4, 5, 9, 11,
308 13, 15, 27, 43, 44, 47, and 48. We also selected samples from 3 patients (17, 64, 64)
309 who were among the patients having the bottom 10% of ACE2 substrate cleavage
310 activity and for which sufficient sample was available for the immunoglobulin depletion
311 procedure as negative control. To determine whether our immunoglobulin depletion
312 procedure also depleted IgM in addition to IgG, selected additional samples for which
313 there sufficient plasma remained for the assays, patients 4, 5, 11, 13, 15, 27, 43, 44, 64,
314 and the pooled healthy donor plasma, and determined IgM concentrations before and
315 after immunoglobulin depletion. We also included a purchased pooled EDTA-
316 anticoagulated plasma sample as an additional control. For both IgG and IgM, we found
317 that our depletion procedure removed more than 99.99% of the immunoglobulins.

318
319 Table 2 show the results of the immunoglobulin depletion protocol applied to the patient
320 plasma samples from these patients. The process depleted IgG by a factor of

321 >>99.99%, leaving IgG in the samples at <2.5 ng/ml for all samples. Table 3 shows the
322 results of assays for IgM run on selected samples for which sufficient sample remained
323 for the assays. For all samples assayed, the immunoglobulin depletion procedure
324 removed >99.9% of IgM.

325

326 We then re-assayed these samples to determine whether immunoglobulin depletion
327 was associated with elimination of the ACE2 substrate cleavage activity (FIG 5), and
328 found that for the 11 tested patients with ACE2 substrate cleavage activity in this cohort,
329 depletion of the immunoglobulin was accompanied by elimination of ACE2 substrate
330 cleavage activity.

331

332 If our hypothesis is correct and the ability to cleave an ACE2 substrate is related to Abs
333 against the RBD, then we should be able to observe a correlation between ACE2
334 substrate cleavage activity and the amount of Ab directed against the RBD in the
335 patients' samples. We assayed for anti-RBD Ab binding activity using a modification of
336 an ImmunoCAP™ Assay activity using a Phadia 250 instrument and S-RBD (FIG 6). We
337 found that there was a significant correlation between the amount of Ab in the patient
338 plasma samples capable of binding the RBD and the ACE2 substrate cleavage activity,
339 suggesting that the ACE2 cleavage activity was related to the amount of anti-RBD Ab
340 present in the plasma sample.

341

342

343

344

345 **Discussion**

346 Our experiments indicate that a fraction of patients with COVID-19 have an activity in
347 plasma capable of cleaving a substrate for ACE2. The ACE2 substrate cleavage activity
348 has divalent cation requirements different from native ACE2 and collocates with
349 immunoglobulin presence during an immunoglobulin depletion procedure, suggesting
350 that these patients may have antibodies with abzyme activity.

351
352 The ACE2 substrate cleavage activity showed a significant correlation with Ab directed
353 against the RBD, further supporting the hypothesis that some anti-RBD Abs have ACE2
354 substrate cleavage activity, but there was considerable spread in the identification of
355 ACE2 substrate cleavage activity observed for different levels of anti-RBD Ab. However,
356 this spread would be expected if only a small fraction of Abs elicited against the RBD in
357 fact had ACE2 substrate cleavage activity, with the initiation and maturation of Ab
358 responses directed against the RBD resulting, in part, from non-specific processes.

359
360 Since abzymes can have a broadened substrate specificity compared to the original
361 enzyme that they mirror, it is possible that abzymes made in response to SARS-COV-2
362 infection may cleave a range of substrates, including substrates that form components
363 of important regulatory cascades, like clotting, blood pressure regulation, and
364 inflammation processes, which could account for aspects of COVID-19 that cannot be
365 directly attributed to viral infection and cell and tissue destruction.

366
367 Our study had several strengths. We studied a moderate number of patients, with
368 samples collected prospectively from acutely hospitalized patients with clearly
369 established COVID-19 relatively early in their disease course, but likely approaching at

370 least 2 weeks following initial infection. The patients almost certainly were not admitted
371 immediately following initial infection and the samples were obtained about a week after
372 admission, providing enough time for the development of an initial antibody response to
373 SARS-CoV-2 infection. We used a standard, widely-employed kit for ACE2 peptide
374 substrate cleavage activity, standard size exclusion columns, protein A/G bead
375 absorption immunoglobulin depletion techniques, and assays for immunoglobulins. The
376 data showing that the ACE2 substrate cleavage activity was present even when there
377 was sufficient EDTA to chelate the Zn^{2+} essential for ACE2 activity suggests that the
378 ACE2 substrate cleavage activity had important characteristics different from native
379 ACE2. The data that the ACE2 substrate cleavage activity was removed from the
380 samples following processing with size exclusion columns and absorption with protein
381 A/G beads suggests that the non- Zn^{2+} -requiring ACE2 substrate cleavage activity co-
382 localizes with immunoglobulin and the data that ACE2 substrate cleavage activity
383 correlated with Ab against the RBD support the hypothesis that the patients with ACE2
384 substrate cleavage activity may have developed abzymes with this activity.

385

386 However, our study has several limitations. We only studied a limited subset of the
387 patients admitted to our hospital, from patients who consented to the sample banking
388 and study and for whom sufficient sample volumes were available. A
389 contemporaneously collected, matched, prospective set of samples from patients
390 without COVID-19 would have been ideal negative controls, but samples from such
391 subjects were not obtained as part of the sample banking effort. We also only
392 conducted the assays on patient samples obtained at a single time, about 7 days after
393 hospitalization, so we have no data from patients who were discharged, transferred, or
394 died prior to day 7 of hospitalization. For this study, we were unable to correlate the

395 presence of ACE-2 abzyme activity with clinical disease features. More importantly, in
396 this study we have no data from patients later in their disease course or following
397 convalescence from the acute disease. Inflammatory, coagulopathic, and physiologic
398 dysregulatory phenomena predominate in the later stages of COVID-19 and at least
399 some aspects of PASC and MIS-C appear to result from immune-mediated phenomena.
400 However, some of these patients are treated with anti-inflammatory agents, including
401 intravenous immunoglobulin, which would make the study of these patients for abzyme-
402 like activity difficult. If abzymes with promiscuous substrate specificities develop in some
403 COVID-19 patients, some of the clinical features of those disorders could potentially be
404 attributed to abzymes, but this study is not able to directly address such additional
405 hypotheses, which would require additional work. In addition, since abzymes can show
406 substantial substrate specificity spread, it is possible that additional patients in our
407 cohort had abzymes with substrate specificity sufficiently divergent from
408 angiotensinogen that it was not detectable using our assay. It is also possible that
409 COVID-19 patients develop anti-RBD antibodies with abzyme-like activity, but that these
410 antibodies have no clinical significance. Some fraction of normal individuals may have
411 ACE2-like abzyme activity, but this activity could have been diluted in the purchased
412 pooled normal control plasma. However, if the abzyme activity in such patients was
413 similar to that observed in the individual positive patients in this study, that activity would
414 still be ~15% of the activity of the positive patients, given the prevalence of detectable
415 abzyme activity in our cohort, and so would have been likely detectable.

416

417 Finally, our study is merely associational. It is possible that we depleted some other,
418 non-immunoglobulin component of COVID-19 patient plasma that has the ability to
419 cleave the ACE2 substrate peptide with our 100 kDa size exclusion plus protein A/G

420 treatment procedure. To unequivocally establish that some COVID-19 patients develop
421 anti-SARS-CoV-2 immune responses that include abzymes, it would be necessary to
422 isolate discrete monoclonal antibodies from patients with ACE2 substrate cleavage
423 activity, and then characterize those monoclonal antibodies in detail. Such work lies
424 outside the perimeters of this current study. It is also possible that some COVID-19
425 patients do, in fact, develop abzymes (ACE2-like – or with other catalytic activity), but
426 that these abzymes have no clinical significance. Additional studies of potential abzyme-
427 like activity in COVID-19 patients with different clinical disease manifestations and at
428 different points in their disease course, including long after acute COVID-19, would be
429 needed to establish the overall significance of abzymes in COVID-19 disease. While
430 understanding the detailed pathogenic significance of abzymes in COVID-19 still
431 requires substantial investigation, the existence of abzymes in COVID-19 is increasingly
432 well-established. In addition to the studies reported here, McConnell and co-workers ⁴¹
433 recently described the existence of abzymes in convalescent plasma COVID-19
434 patients capable of cleaving spike protein with virus neutralization. That two different
435 groups independently found evidence of abzyme activity in plasma from COVID-19
436 patients provides significant support for the hypothesis that COVID-19 patients can
437 develop antibodies with proteolytic activity.

438

439 Nevertheless, our study offers potential additional insight into some of the difficult-to-
440 understand clinical features of COVID-19, and if some of the difficult manifestations of
441 COVID-19 are related to the induction of antibodies with abzyme-like activity, that
442 finding may suggest new therapeutic interventions. Some other viruses also have also
443 evolved to use enzymes located on the target host cell surface as their receptors, so it
444 is conceivable that those other viral infections may also elicit clinically problematic anti-

445 viral antibodies. The number of spike protein RBDs presented to the immune system in
446 a natural infection is vastly greater than the number of RBDs presented to the immune
447 system following vaccination, offering many more opportunities for the induction of wide-
448 ranging antibody responses, unlike the antigen exposure resulting from vaccination.
449 While complications following vaccination are very rare and the risk-benefit calculation
450 greatly favors vaccination, some of the adverse side effects of SARS-CoV-2 vaccines
451 might also be attributable to the rare induction of anti-RBD antibodies with catalytic
452 activity.

453

454 **Institutional Review Board Statement:** The sample collection protocol was approved
455 by the UVA IRB (HSR #200110), and approval was obtained to work on the specimens
456 (HSR #HSR200362).

457

458 **Informed Consent Statement:** Informed consent was obtained from all participants
459 involved in the study.

460 **Data Availability Statement:** Data is presented in the manuscript and the
461 supplements. Raw data can be obtained on request.

462

463 **Acknowledgments and Funding:** The study was supported by internal funding from
464 the University of Virginia, including the Manning Fund for COVID-19 Research at UVA
465 the Ivy Foundation, the Pendleton Laboratory Fund for Pediatric Infectious Disease
466 Research, a College Council Minera Research Grant, the Coulter Foundation, and
467 NIAID, NIH (R01 AI176515) with sample acquisition costs supported by the HHV-6
468 Foundation. We thank the study participants for graciously agreeing to be research
469 participants, and the research support staff who enrolled the study participants (led by

470 Linda Bailes RN, Allison Raymond RN and Sarah Struchen RN). We also thank the
471 University of Virginia Biorepository and Tissue Research Facility for processing the
472 samples used in the study and for providing specimens (Technical Director, Patcharin
473 Pramoonjago PhD).

474

475 **Conflicts of Interest:** The authors declare no conflict of interest.

476

477 **Tables and Figures**

478

479

480

Table 1. Patient Demographic and Clinical Characteristics (cohort previously described in ³⁵)	
(IQR: interquartile range)	
Characteristic	N = 67, median, (IQR)
<i>Age at Admission</i>	60 (48, 66)
<i>First Weight (kg)</i>	91 (76, 112)
Unknown	1
<i>Height (m)</i>	1.68 (1.60, 1.83)
Unknown	6
<i>Gender</i>	
Female	28 (42%)
Male	39 (58%)
<i>Race</i>	
African American	23 (34%)
Native American	1 (1.5%)
Caucasian	31 (46%)
Other	12 (18%)
<i>Smoking Status</i>	
Current	1 (2.1%)
Former	14 (29%)
Never	24 (50%)
Unknown	9 (19%)
NA	19
<i>Need for ICU</i>	
No	28 (42%)
Yes	39 (58%)
<i>Need for Intubation</i>	
No	41 (61%)
Yes	26 (39%)
<i>Blood Type</i>	
A-	2 (4.8%)
A+	14 (33%)
AB+	1 (2.4%)
B+	3 (7.1%)
O-	1 (2.4%)
O+	21 (50%)
Not determined	25
<i>Highest Temperature</i>	
<38	42 (49%)
101	12 (18%)
>38.5	12 (18%)
>40	1 (1.5%)
<i>Length of Stay (Days)</i>	10 (5, 22)
<i>Time to Death (Days)</i>	
6	1
10-20	2
20-30	3
>30	2 (
<i>Highest D-Dimer</i>	605 (280, 2,074)
<i>Highest CRP</i>	10 (4, 16)
<i>BMI</i>	33 (27, 38)
<i>Need for Vasopressors</i>	
Yes	44 (66%)
<i>Dexamethasone</i>	
Yes	41 (61%)
<i>Prednisone</i>	
Yes	3 (13%)
<i>Methylprednisolone</i>	
Yes	5 (22%)
<i>Tocilizumab</i>	
Yes	4 (6%)
<i>Remdesivir</i>	
Yes	27 (40%)
<i>Creatinine</i>	1.00 (0.80, 1.45)
<i>Hgb</i>	12.4 (10.8, 13.6)
<i>IFNa3</i>	45 (36, 72)
Not determined	45
<i>Highest Ferritin</i>	1277 (7, 7161)
Not determined	5
<i>Highest Troponin</i>	
<0.04	47 (73%)
0.04-0.4	12 (18%)
>0.6	3 (5%)
Not determined	5
<i>Highest Creatinine</i>	1.10 (0.90, 1.80)

556 Table 2. Plasma IgG concentration before and after antibody depletion for selected
557 patients exhibiting ACE2 substrate cleavage activity in FIG 2, then re-assayed for ACE2
558 substrate cleavage activity with results shown in FIG 4.
559

560

Patient (#)	IgG Concentration		IgG depletion efficiency (%)
	Pre ^a mg/ml	Post ^b ng/ml	
4	14.62	0.67	>99.99%
5	12.50	1.48	>99.99%
9	24.40	0.96	>99.99%
11	75.41	0.17	>99.99%
13	26.35	2.46	>99.99%
15	13.27	2.47	>99.99%
27	10.53	2.40	>99.99%
43	29.07	0.87	>99.99%
44	11.17	2.29	>99.99%
47	13.15	1.85	>99.99%
48	12.32	2.06	>99.99%

561
562
563

a: IgG concentration in plasma before antibody depletion
b: IgG concentration in plasma after antibody depletion by ultrafiltration and Protein A/G beads

564 Table 3. Plasma IgM concentration before and after antibody depletion for selected
565 patients.
566

Patient (#)	IgM Concentration (mg/ml)		IgM Depletion Efficiency (%)
	Pre ^a	Post ^b	
4	0.875	1.43E-05	>99.99%
5	0.753	1.44E-05	>99.99%
11	0.7916	7.99E-06	>99.99%
13	0.644	1.41E-05	>99.99%
15	2.250	1.08E-05	>99.99%
27	0.549	1.40E-05	>99.99%
43	1.560	1.34E-05	>99.99%
44	3.243	1.41E-05	>99.99%
64	0.915	8.22E-06	>99.99%
Pooled Healthy Donor	0.4852	1.3568E-05	>99.99%

567 a: IgM concentration in plasma before antibody depletion

568 b: IgM concentration in plasma after antibody depletion by ultrafiltration and Protein A/G beads

569

570

571 **Figure Legends**

572

573 FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The SARS-
574 COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the surface of a
575 potential host cells. The RBD has a partial negative image of ACE2. Some antibodies
576 against the RBD may then have a conformation sufficiently like ACE2 to have
577 proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further
578 suggests that the catalytic activity of some antibodies will have a substrate specificity
579 like ACE2, but because the negative image of RBD present antibodies is imperfect,
580 some antibodies with proteolytic activity will have an altered substrate specificity,
581 potentially affecting multiple proteolytic regulatory cascades.

582

583 FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in
584 undiluted EDTA-anticoagulated pooled plasma samples with and without added ZnCl₂.
585 ACE2 is a Zn²⁺ metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was
586 detectable when exogenous ACE2 was added to the plasma, unless Zn²⁺ was also
587 added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2.
588 Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions,
589 indicating that the activity was specific for ACE2. The findings indicate that no native
590 ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any
591 ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should
592 be due to something other than ACE or another Zn²⁺ metalloprotease.

593

594 FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with
595 COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the
596 fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus

597 control samples. Several patients, including the 11 patients we selected for further study
598 (4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) because they had among the top 20% of RFU
599 values and had sufficient plasma sample remaining for the immunoglobulin depletion
600 protocol, showed an ability to cleave ACE2 substrate. (HDP: commercially purchased
601 pooled healthy donor plasma; HDP+P.C: HDP with added recombinant human ACE2;
602 HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma from negative
603 samples).

604

605 FIG 4. Scatter plot of the background corrected RFU values for the plasma samples
606 from the 67 patients evaluated in this study. The top 20% of values are plotted in red,
607 the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top
608 20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays
609 before and after immunoglobulin depletion shown in FIG 5.

610

611 FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin
612 depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9,
613 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which
614 we had sufficient plasma for immunoglobulin depletion, before (blue points) and after
615 (red points) immunoglobulin depletion by a 100 KDa size exclusion column followed by
616 protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays
617 before and after immunoglobulin depletion for pooled patient plasma (PPP) negative
618 controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among
619 the bottom 10% of RFU values and had sufficient plasma remaining for the
620 immunoglobulin depletion protocol. The data suggest that for the 11 patients

621 demonstrating ACE2 substrate cleavage activity in this cohort, the ACE2 substrate

622 cleavage activity was depleted in an immunoglobulin-associated manner.

623

624 FIG 6. Correlation of ACE2 substrate cleavage activity (ACE2 Activity) with anti-RBD

625 antibody (Ab Against RBD) in patient plasma. Anti-RBD antibody concentrations in

626 plasma samples were determined using ImmunoCAP™ antibody binding assay. The


627 negative control pooled human plasma is indicated by the red symbol. The patient

628 plasma samples are indicated in green. The negative control plasma values were

629 omitted in the calculation of the r- and p-values.


630

631 FIG 1. FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The
632 SARS-COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the
633 surface of a potential host cells. The RBD has a partial negative image of ACE2. Some
634 antibodies against the RBD may then have a conformation sufficiently like ACE2 to
635 have proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further
636 suggests that the catalytic activity of some antibodies will have a substrate specificity
637 like ACE2, but because the negative image of RBD present antibodies is imperfect,
638 some antibodies with proteolytic activity will have an altered substrate specificity,
639 potentially affecting multiple proteolytic regulatory cascades.
640
641
642




643
644

645 FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in
646 undiluted EDTA-anticoagulated pooled plasma samples with and without added $ZnCl_2$.
647 ACE2 is a Zn^{2+} metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was
648 detectable when exogenous ACE2 was added to the plasma, unless Zn^{2+} was also
649 added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2.
650 Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions,
651 indicating that the activity was specific for ACE2. The findings indicate that no native
652 ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any
653 ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should
654 be due to something other than ACE or another Zn^{2+} metalloprotease.
655




656
657

658 FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with
659 COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the
660 fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus
661 control samples. We identified plasma from 11 patients (4, 5, 9, 11, 13, 15, 27, 43, 44,
662 47, 48) that showed an ability to cleave ACE2 substrate. (HDP: commercially
663 purchased pooled healthy donor plasma; HDP+P.C: HDP with added recombinant
664 human ACE2; HDP+P.C.+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma
665 from negative samples).




666
667

668 FIG 4. Scatter plot of the background corrected RFU values for the plasma samples
669 from the 67 patients evaluated in this study. The top 20% of values are plotted in red,
670 the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top
671 20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays
672 before and after immunoglobulin depletion shown in FIG 5.
673
674
675




676
677

678 FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin
679 depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9,
680 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which
681 we had sufficient plasma for immunoglobulin depletion, before (blue points) and after
682 (red points) immunoglobulin depletion by a 100 kDa size exclusion column followed by
683 protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays
684 before and after immunoglobulin depletion for pooled patient plasma (PPP) negative
685 controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among
686 the bottom 10% of RFU values and had sufficient plasma remaining for the
687 immunoglobulin depletion protocol. The data suggest that for the 11 patients
688 demonstrating the highest ACE2 substrate cleavage activity in this cohort, the ACE2
689 substrate cleavage activity was depleted in an immunoglobulin-associated manner.
690



691
692

693 FIG 6. Correlation of ACE2 substrate cleavage activity (ACE2 Activity) with anti-RBD
694 antibody (Ab Against RBD) in patient plasma. Anti-RBD antibody concentrations in
695 plasma samples were determined using ImmunoCAP™ antibody binding assay. The
696 negative control pooled human plasma is indicated by the red symbol. The patient
697 plasma samples are indicated in green. The negative control plasma values were
698 omitted in the calculation of the r- and p-values.
699
700



701
702
703
704
705
706
707

708 References

- 709 1. Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC,
710 Isenhour C, Clarke KR, Evans ME, Chu VT, Biggs HM, Kirking HL, Gerber SI, Hall AJ,
711 Fry AM, Oliver SE. Persons Evaluated for 2019 Novel Coronavirus - United States,
712 January 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Feb 14;69(6):166-70. PMC7017962
713
- 714 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X,
715 Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L,
716 Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients
717 infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020 Feb
718 15;395(10223):497-506. PMC7159299
719
- 720 3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
721 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
722 72 314 Cases From the Chinese Center for Disease Control and Prevention. *Jama.*
723 2020 Apr 7;323(13):1239-42.
724
- 725 4. Chung TW, Sridhar S, Zhang AJ, Chan KH, Li HL, Wong FK, Ng MY, Tsang RK,
726 Lee AC, Fan Z, Ho RS, Luk SY, Kan WK, Lam SH, Wu AK, Leung SM, Chan WM, Ng
727 PY, To KK, Cheng VC, Lung KC, Hung IF, Yuen KY. Olfactory Dysfunction in
728 Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic
729 Review. *Open Forum Infect Dis.* 2020 Jun;7(6):ofaa199. PMC7284010
730
- 731 5. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, Gao Y, Cai L, Wang Z, Yin P, Wang
732 Y, Tang L, Deng J, Mei H, Hu Y. Haematological characteristics and risk factors in the
733 classification and prognosis evaluation of COVID-19: a retrospective cohort study.
734 *Lancet Haematol.* 2020 Sep;7(9):e671-e8. PMC7351397
735
- 736 6. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B,
737 Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van
738 Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M,
739 Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo
740 C, Feldmann M, Parekh S, Merad M, Gnajatic S. An inflammatory cytokine signature
741 predicts COVID-19 severity and survival. *Nat Med.* 2020 Oct;26(10):1636-43.
742 PMC7869028
743
- 744 7. De Rose DU, Pugnali F, Cali M, Ronci S, Caoci S, Maddaloni C, Martini L,
745 Santisi A, Dotta A, Auriti C. Multisystem Inflammatory Syndrome in Neonates Born to
746 Mothers with SARS-CoV-2 Infection (MIS-N) and in Neonates and Infants Younger
747 Than 6 Months with Acquired COVID-19 (MIS-C): A Systematic Review. *Viruses.*
748 2022;14(4):750.
749
- 750 8. Yousaf AR, Cortese MM, Taylor AW, Broder KR, Oster ME, Wong JM, Guh AY,
751 McCormick DW, Kamidani S, Schlaudecker EP, Edwards KM, Creech CB, Staat MA,
752 Belay ED, Marquez P, Su JR, Salzman MB, Thompson D, Campbell AP. Reported
753 cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA
754 who received a COVID-19 vaccine, December, 2020, through August, 2021: a
755 surveillance investigation. *Lancet Child Adolesc Health.* 2022 Feb 22. PMC8864018

- 756
757 9. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk
758 factors, and management. *Bmj*. 2021 Jul 26;374:n1648.
759
- 760 10. Su Y, Yuan D, Chen, D.G., Ng, R.H., Wang, K., Choi, J., Li, S., Hong, S., Zhang
761 R, Xie, J., Kornilov, S.A., Scherler, K., Pavlovitch-Bedzyk, A.J., Dong, S., Lausted, C.,
762 Lee, I., Fallen S, Dai, C.L., Baloni, P., Smith, B., Duvvuri, V.R., Anderson, K.G., Li, J.,
763 Yang, F., Duncombe, C.J. M, D.J., Rostomily, C., Troisch, P., Zhou, J., Mackay, S.,
764 DeGottardi, Q., May, D.H., Taniguchi R, Gittelman, R.M, Klinger, M., Snyder, T.M,
765 Roper, R., Wojciechowska, G., Murray, K., Edmark R, Evans, S., Jones, L., Zhou, Y.,
766 Rowen, L., Liu, R., Chour, W., Algren, H.A, Berrington,, W.R. W, J.A., Cochran, R.A.,
767 Micikas, M.E., the ISB-Swedish COVID19 Biobanking Unit, Terri Wrin, Petropoulos,
768 C.J., Cole, H.R., Fischer, T.D., Wei, W., Hoon, D.S.B., Price, N.D., Subramanian, N.,,
769 Hill JA, Hadlock, J., Magis, A.T., Ribas, A., Lanier, L.L., Boyd, S.D., Bluestone, J.A.,
770 Chu, H., Hood,, L. G, R., Greenberg, P.D., Davis, M.M., Goldman, J.D., Heath, J.R.,
771 Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. *Cell*. 2022.
772
- 773 11. Hanidziar D, Bittner EA. Hypotension, Systemic Inflammatory Response
774 Syndrome, and COVID-19: A Clinical Conundrum. *Anesth Analg*. 2020
775 Sep;131(3):e175-e6. PMC7302068
776
- 777 12. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, Lim
778 PB. Autonomic dysfunction in 'long COVID': rationale, physiology and management
779 strategies. *Clin Med (Lond)*. 2021 Jan;21(1):e63-e7. PMC7850225
780
- 781 13. Koudelka M, Sovová E. COVID-19 Causing Hypotension in Frail Geriatric
782 Hypertensive Patients? *Medicina (Kaunas)*. 2021 Jun 18;57(6). PMC8235779
783
- 784 14. Hillmeister P, Persson PB. The Kallikrein–Kinin system. *Acta Physiologica*.
785 2012;206(4):215-9.
786
- 787 15. Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. Crosstalk between the
788 renin-angiotensin, complement and kallikrein-kinin systems in inflammation. *Nat Rev*
789 *Immunol*. 2022 Jul;22(7):411-28. PMC8579187
790
- 791 16. Martens CP, Van Mol P, Wauters J, Wauters E, Gangnus T, Noppen B,
792 Callewaert H, Feyen JHM, Liesenborghs L, Heylen E, Jansen S, Pereira LCV, Kraisin S,
793 Guler I, Engelen MM, Ockerman A, Van Herck A, Vos R, Vandenbrielle C, Meersseman
794 P, Hermans G, Wilmer A, Martinod K, Burckhardt BB, Vanhove M, Jacquemin M,
795 Verhamme P, Neyts J, Vanassche T. Dysregulation of the kallikrein-kinin system in
796 bronchoalveolar lavage fluid of patients with severe COVID-19. *eBioMedicine*. 2022
797 2022/09/01/;83:104195.
798
- 799 17. Carvalho PRd, Sirois P, Fernandes PD. The role of kallikrein-kinin and renin-
800 angiotensin systems in COVID-19 infection. *Peptides*. 2021 2021/01/01/;135:170428.
801
- 802 18. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. *Science*. 1986 Dec
803 19;234(4783):1566-70.
804

- 805 19. Pollack SJ, Jacobs JW, Schultz PG. Selective chemical catalysis by an antibody.
806 Science. 1986 Dec 19;234(4783):1570-3.
807
- 808 20. Hilvert D. Critical analysis of antibody catalysis. *Annu Rev Biochem.*
809 2000;69:751-93.
810
- 811 21. Bar-Even A, Noor E, Savir Y, Liebermeister W, Davidi D, Tawfik DS, Milo R. The
812 moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme
813 parameters. *Biochemistry.* 2011 May 31;50(21):4402-10.
814
- 815 22. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic
816 hydrolysis of vasoactive intestinal peptide by human autoantibody. *Science.* 1989 Jun
817 9;244(4909):1158-62.
818
- 819 23. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov
820 AG. DNA hydrolyzing autoantibodies. *Science.* 1992 May 1;256(5057):665-7.
821
- 822 24. Paul S, Li L, Kalaga R, Wilkins-Stevens P, Stevens FJ, Solomon A. Natural
823 catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL
824 fragment. *J Biol Chem.* 1995 Jun 23;270(25):15257-61.
825
- 826 25. Thiagarajan P, Dannenbring R, Matsuura K, Tramontano A, Gololobov G, Paul S.
827 Monoclonal antibody light chain with prothrombinase activity. *Biochemistry.* 2000 May
828 30;39(21):6459-65.
829
- 830 26. Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg JY, Borel-Derlon
831 A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S. Factor VIII hydrolysis
832 mediated by anti-factor VIII autoantibodies in acquired hemophilia. *J Immunol.* 2008 Jun
833 1;180(11):7714-20.
834
- 835 27. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N,
836 Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. Catalytic activity of
837 antibodies against factor VIII in patients with hemophilia A. *Nat Med.* 1999
838 Sep;5(9):1044-7.
839
- 840 28. Ponomarenko NA, Durova OM, Vorobiev, II, Belogurov AA, Jr., Kurkova IN,
841 Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM,
842 Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC, 3rd, Thomas D,
843 Friboulet A, Gabibov AG. Autoantibodies to myelin basic protein catalyze site-specific
844 degradation of their antigen. *Proc Natl Acad Sci U S A.* 2006 Jan 10;103(2):281-6.
845 PMC1324791
846
- 847 29. Ponomarenko NA, Vorobiev, II, Alexandrova ES, Reshetnyak AV, Telegin GB,
848 Khaidukov SV, Avalle B, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov
849 AG. Induction of a protein-targeted catalytic response in autoimmune prone mice:
850 antibody-mediated cleavage of HIV-1 glycoprotein GP120. *Biochemistry.* 2006 Jan
851 10;45(1):324-30.
852

- 853 30. Avalle B, Mistro D, Thomas D, Friboulet A. Polyclonal catalytic anti-idiotypic
854 antibodies with a beta-lactamase activity. *Ann N Y Acad Sci.* 1996 Oct 12;799:172-5.
855
- 856 31. Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Abzyme generation using
857 an anti-idiotypic antibody as the "internal image" of an enzyme active site. *Appl*
858 *Biochem Biotechnol.* 1994 May-Jun;47(2-3):229-37; discussion 37-9.
859
- 860 32. Izadyar L, Friboulet A, Remy MH, Roseto A, Thomas D. Monoclonal anti-idiotypic
861 antibodies as functional internal images of enzyme active sites: production of a catalytic
862 antibody with a cholinesterase activity. *Proc Natl Acad Sci U S A.* 1993 Oct
863 1;90(19):8876-80. PMC47463
864
- 865 33. Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Antiidiotypic antibodies as
866 functional internal images of enzyme-active sites. *Ann N Y Acad Sci.* 1995 Mar
867 31;750:265-70.
868
- 869 34. Ponomarenko NA, Pillet D, Paon M, Vorobiev, II, Smirnov IV, Adenier H, Avalle
870 B, Kolesnikov AV, Kozyr AV, Thomas D, Gabibov AG, Friboulet A. Anti-idiotypic
871 antibody mimics proteolytic function of parent antigen. *Biochemistry.* 2007 Dec
872 18;46(50):14598-609.
873
- 874 35. Brooks B, Tancredi C, Song Y, Mogus AT, Huang M-LW, Zhu H, Phan TL, Zhu
875 H, Kadl A, Woodfolk J. Epstein–Barr Virus and Human Herpesvirus-6 Reactivation in
876 Acute COVID-19 Patients. *Viruses.* 2022;14(9):1872.
877
- 878 36. García-Escobar A, Vera-Vera S, Jurado-Román A, Jiménez-Valero S, Galeote G,
879 Moreno R. Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic
880 Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-
881 19. *Biomolecules.* 2022 Jan 5;12(1). PMC8774087
882
- 883 37. Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J,
884 Harville TO. Development of ACE2 autoantibodies after SARS-CoV-2 infection. *PLoS*
885 *One.* 2021;16(9):e0257016. PMC8415618
886
- 887 38. Tanna A, Guarino L, Tam FWK, Rodriguez-Cubillo B, Levy JB, Cairns TD, Griffith
888 M, Tarzi RM, Caplin B, Salama AD, Cook T, Pusey CD. Long-term outcome of anti-
889 neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the
890 international histological classification and other prognostic factors. *Nephrology Dialysis*
891 *Transplantation.* 2014;30(7):1185-92.
892
- 893 39. Xiao F, Burns KD. Measurement of angiotensin converting enzyme 2 activity in
894 biological fluid (ACE2). *Hypertension: Springer;* 2017. p. 101-15.
- 895 40. Keshavarz B, Wiencek JR, Workman LJ, Straesser MD, Muehling LM, Canderan
896 G, Drago F, Bonham CA, Sturek JM, Ramani C, McNamara CA, Woodfolk JA, Kadl A,
897 Platts-Mills TAE, Wilson JM. Quantitative Measurement of IgG to Severe Acute
898 Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP. *Int Arch Allergy*
899 *Immunol.* 2021;182(5):417-24. PMC8018212
900

901 41. McConnell SA, Sachithanandham J, Mudrak NJ, Zhu X, Farhang PA, Cordero
902 RJB, Wear MP, Shapiro JR, Park HS, Klein SL, Tobian AAR, Bloch EM, Sullivan DJ,
903 Pekosz A, Casadevall A. Spike-protein proteolytic antibodies in COVID-19 convalescent
904 plasma contribute to SARS-CoV-2 neutralization. Cell Chem Biol. 2023 Jul
905 20;30(7):726-38.e4. PMC10288624
906
907